Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of KS101 in Healthy Volunteers
NCT07143331Phase 1Not yet recruiting
- Start
- Aug 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KS101 in chronic kidney disease (CKD) and Alzheimer's disease (AD) (6 arms). Primary endpoint: Safety and Tolerability (AEs, Physical Exam, Labs, Vital Signs, ECG) up to 63 days. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
KS101
03
Conditions
chronic kidney disease (CKD)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07143331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07143331.